Prime Medicine announced that company management will participate in three upcoming healthcare and biotech conferences in March 2026, including fireside chats at the TD Cowen Health Care Conference and Citizens Life Sciences Conference, as well as 1x1 meetings at the Jefferies Biotech on the Beach Summit. Live webcasts of the fireside chats will be available on the company's website.

The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating significant efficacy and safety profiles.

Prime Medicine published Phase 1/2 clinical data for PM359, an investigational gene therapy for chronic granulomatous disease, demonstrating safety and early clinical efficacy in two patients with promising results in neutrophil restoration and disease symptom improvement.

Prime Medicine reported Q3 2025 financial results, highlighting progress in genetic therapies for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file IND/CTA applications in 2026-2027 and new preclinical data to be presented at AASLD.

Prime Medicine reported Q2 2025 earnings with a net loss of $52.6 million, below analyst estimates. The company demonstrated clinical proof-of-concept for Prime Editing in chronic granulomatous disease and extended its cash runway into 2027 through strategic restructuring and funding.

Prime Medicine is conducting a public offering of 38 million shares at $3.30 per share, expecting to raise approximately $125.4 million. The Cystic Fibrosis Foundation will purchase 1,818,181 shares, and the offering is expected to close on August 1, 2025.

Prime Medicine, a clinical-stage biotech company, announced a new preclinical program targeting alpha-1 antitrypsin deficiency, a genetic disorder affecting lung and liver function. Investors reacted positively to the company's plans to file an Investigational New Drug Application by mid-2026, but the development risks associated with clinical-stage biotechs remain.

Prime Medicine announced a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder. The program leverages Prime Medicine's proprietary Prime Editing technology and is expected to file an IND/CTA in mid-2026.

Prime Medicine reported progress in its Wilson's Disease program, including in vivo data demonstrating efficient correction of disease-causing mutations. The company also announced a strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies and expects to report initial data from its Phase 1/2 trial of PM359 for p47phox CGD in 2025.

Prime Medicine, a biotechnology company, announced that it will participate in several upcoming healthcare conferences, including the Guggenheim Healthcare Innovation Conference, Stifel 2024 Healthcare Conference, and Jefferies London Healthcare Conference. The company is focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform.

This article discusses a diverse set of growth stocks in various industries, including AI, space, biotech, and emerging technologies. The author highlights the potential rewards and risks of investing in individual growth stocks, and provides an overview of 14 stocks in his tax-advantaged portfolios.

Prime Medicine, a gene-editing company, announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for T-cell therapies. This news sent Prime Medicine's share price up nearly 12%, outperforming the S&P 500's 0.4% gain.